Skip to main content

Advertisement

SpringerLink
Log in

Survival in progressive systemic sclerosis with pulmonary involvement: a single-center experience in Istanbul, Turkey

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The objective of the current study was to determine survival and factors that affect survival in progressive systemic sclerosis (SSc) with pulmonary involvement. A total of 102 SSc patients with pulmonary involvement, diagnosed between 1994 and 2008, enrolled into the study. Pulmonary involvement was defined based on the presence of interstitial changes on high-resolution CT (HRCT). Demographical, clinical, radiological, and laboratory data of the patients were found from patient records and were used for the evaluation of survival. The mean age of the patients at diagnosis was 50 ± 12 years. In follow-up, 22 (21.5%) patients were deceased. The mean age of the patients at death was 55 ± 12 years. Seventy-eight percent of known causes of mortality were related to pulmonary complications. After any initial systemic manifestation of disease, the mean survival was 447 ± 27 months and 5, 10, 15, and 20 year survival rates were 99, 92, 83, and 72%, respectively. The mean survival after initial pulmonary manifestation was 269 ± 23 months and 5, 10 and 15 year survival rates were 91, 73 and 57%, respectively. Mean survival was 113 ± 5 months, and 5- and 10-year survival rates after the lung involvement detected with HRCT were 85 and 66%, respectively. Pulmonary artery hypertension, disease onset after the age of 40, and honeycombing on HRCT were associated with poor survival. Our data suggest that pulmonary involvement is the most important determinant factor for poor prognosis in patients with SSc. Therefore, echocardiography, pulmonary function tests, and HRCT should be performed in early stages of the disease for early diagnosis of pulmonary artery hypertension and lung involvement before irreversible vascular and interstitial changes exist.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Roufosse FE, de Bellefon LM (2007) Systemic sclerosis. Acta Clin Belg 62:323–329

    PubMed  CAS  Google Scholar 

  2. Du Bois RM (2007) Mechanisms of scleroderma-induced lung disease. Proc Am Thorac Soc 4:434–438

    Article  PubMed  Google Scholar 

  3. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165:1581–1586

    Article  PubMed  Google Scholar 

  4. Benan M, Hande I, Gul O (2007) The natural course of progressive systemic sclerosis patients with interstitial lung involvement. Clin Rheumatol 26:349–354

    Article  PubMed  Google Scholar 

  5. Simeón CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M et al (2003) Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 42:71–75

    Article  Google Scholar 

  6. Jacobsen S, Halberg P, Ullman S (1998) Mortality and causes of death of 344 Danish patients with systemic sclerosis. Br J Rheumatol 37(7):750–755

    Article  PubMed  CAS  Google Scholar 

  7. Hesselstrand R, Scheja A, Akesson A (1998) Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 57:682–686

    Article  PubMed  CAS  Google Scholar 

  8. Bryan C, Howard Y, Brennan P, Black C, Silman A (1996) Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 35:1122–1126

    Article  PubMed  CAS  Google Scholar 

  9. Abu-Shakra M, Lee P (1995) Mortality in systemic sclerosis: a comparison with the general population. J Rheumatol 22:2100–2102

    PubMed  CAS  Google Scholar 

  10. Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA Jr, Wright TM (1999) Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 42:465–474

    Article  PubMed  CAS  Google Scholar 

  11. Altman RD, Medsger TA Jr, Bloch DA, Michel BA (1991) Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34:403–413

    Article  PubMed  CAS  Google Scholar 

  12. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ et al (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48:2246–2255

    Article  PubMed  Google Scholar 

  13. Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944

    Article  PubMed  Google Scholar 

  14. Subcoomittee for Scleroderma Criteria of tht American Rheumatism Association Diagnostic, therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis. Arthritis Rheum 23:581–590

    Article  Google Scholar 

  15. Al-Dhaher FF, Pope JE, Ouimet JM (2010) Determinants of morbidity and mortality of systemic Sclerosis in Canada. Semin Arthritis Rheum 39:269–277

    Article  PubMed  Google Scholar 

  16. Alamanos Y, Tsifetaki N, Voulgari PV, Siozos C, Tsamandouraki K, Alexiou GA et al (2005) Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. Semin Arthritis Rheum 34:714–720

    Article  PubMed  Google Scholar 

  17. Bennett R, Bluestone R, Holt PJ, Bywaters EG (1971) Survival in scleroderma. Ann Rheum Dis 30(6):581–588

    Article  Google Scholar 

  18. Nishioka K, Katayama I, Kondo H, Shinkai H, Ueki H, Tamaki K (1996) Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). Scleroderma Research Committee Japan. J Dermatol 23:677–682

    PubMed  CAS  Google Scholar 

  19. Abu-Shakra M, Guillemin F, Lee P (1993) Cancer in systemic sclerosis. Arthritis Rheum 36:460–464

    Article  PubMed  CAS  Google Scholar 

  20. Koh ET, Lee P, Gladman DD, Abu-Shakra M (1996) Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 35:989–993

    Article  PubMed  CAS  Google Scholar 

  21. Trad S, Amoura Z, Beigelman C, Haroche J, Costedoat N, Boutin le TH (2006) Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 54:184–191

    Article  PubMed  Google Scholar 

  22. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP (2006) Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92:926–932

    Article  PubMed  CAS  Google Scholar 

  23. Pope JE, Lee P, Baron M, Dunne J, Smith D, Docherty PS et al (2005) Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 32:1273–1278

    PubMed  Google Scholar 

  24. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P (2003) Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 62:728–731

    Article  PubMed  CAS  Google Scholar 

  25. Rosenthal AK, McLaughlin JK, Linet MS, Persson I (1993) Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis 52:531–533

    Article  PubMed  CAS  Google Scholar 

  26. Goh NS, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP (2007) Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 56:2005–2012

    Article  PubMed  Google Scholar 

  27. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666

    Article  PubMed  CAS  Google Scholar 

  28. Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P (2001) Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 28:2454–2459

    PubMed  CAS  Google Scholar 

  29. Fischer A, Swigris JJ, Groshong SD, Cool SD, Sahin H, Lynch DA (2008) Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features and survival. Chest 134:601–605

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Pulmonary Disease, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey

    Ferit zuhur, Cigdem Zuhur, Benan Musellim & Gul Ongen

  2. Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey

    Sayid Shafi Zuhur

  3. Endocrinology and Metabolism Clinic, Sisli Etfal Training and Research Hospital, Istanbul, Turkey

    Sayid Shafi Zuhur

Authors
  1. Ferit zuhur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sayid Shafi Zuhur
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cigdem Zuhur
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Benan Musellim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gul Ongen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ferit zuhur.

Rights and permissions

Reprints and permissions

About this article

Cite this article

zuhur, F., Zuhur, S.S., Zuhur, C. et al. Survival in progressive systemic sclerosis with pulmonary involvement: a single-center experience in Istanbul, Turkey. Rheumatol Int 32, 1655–1661 (2012). https://doi.org/10.1007/s00296-011-1842-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-011-1842-x

Keywords

Search

Navigation